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Aim: The aim of this study was to compare both the efﬁcacy and safety proﬁle of the WHO-
recommended, dual therapy (doxycycline–rifampin) to a quinolone-based, triple therapy
(doxycycline–rifampin–levoﬂoxacin) for treating acute/subacute brucellosis.
Patients and methods: We  studied 107 consecutive, naïve patients with acute/subacute bru-
cellosis admitted to Assiut University Hospital. Patients were randomly allocated to receive
the  dual therapy of doxycycline–rifampin (group-A) or to receive the triple therapy of
doxycycline–rifampin–levoﬂoxacin (group-B). Acute/subacute brucellosis was diagnosed
based on the presence of: (1) contact with animals or fresh animal products, (2) sugges-
tive clinical manifestations of less than one-year duration, and (3) positive antibody titer
(1:160) by standard tube agglutination test.
Results: There was no signiﬁcant difference between the two groups regarding their demo-
graphic data. Fever was the most frequent manifestation (96.3%). Epigastric pain was the
most  frequent adverse effect of treatment (12.1%). Group-A patients had a signiﬁcantly
higher relapse rate compared to group-B patients (22.6% versus 9.3%, p-value = 0.01). The
rate of treatment adverse effects was higher among group-B patients, although not reaching
statistical signiﬁcance (20.4% versus 11.3%, p-value = 0.059).
Conclusions: Adding levoﬂoxacin to the dual therapy for acute/subacute brucellosis
(doxycycline–rifampin) may increase its efﬁcacy in terms of lowering the relapse rate of theer scadisease. Further, largdual  therapy for brucellos
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ntroduction
ore  than 500,000 cases of brucellosis are reported yearly
o the World Health Organization (WHO) from 100 countries.
eroprevalence of brucellosis in Assiut Governorate (Egypt)
as estimated to be 1.29% among the general population.1
acteria of the genus Brucella cause disease with protean man-
festations. Infection is transmitted to humans from animals
s a consequence of occupational exposure or ingestion of
ontaminated milk products. Brucella abortus infection occurs
orldwide with a reservoir in cattle. It is usually associ-
ted with mild to moderate sporadic disease; suppurative
r disabling complications are rare. Brucella melitensis, with
 reservoir in sheep, goats, and camels may cause severe,
cute disease and disabling complications. It accounts for the
ajority of cases, distributed primarily in the Mediterranean
egion, Latin America, the Arabian Gulf, and the Indian sub-
ontinent. Clinically, human brucellosis can be conveniently
ut arbitrarily divided into subclinical illness, acute or suba-
ute disease, localized disease and complications, relapsing
nfection, and chronic disease. The WHO  recommends doxy-
ycline (200 mg/day) plus rifampin (600–900 mg/day) orally for
ix weeks for treating brucellosis. Up to 10% of patients with
rucellosis experience relapses after antimicrobial therapy.
elapses usually occur three to six months after comple-
ion of therapy but may be seen up to two years after
reatment.2
Combination drug therapy of brucellosis leads to short-
ning duration of symptoms, and decreases morbidity while,
ingle drug therapy is associated with more  relapse episodes
nd a higher rate of drug resistance.3 Therapeutic failure and
elapse develop in 8% and 16%, respectively, of patients with
cute brucellosis receiving doxycycline plus rifampin for 45
ays compared to 2% and 5.2% among patients receiving doxy-
ycline plus streptomycin for the same duration.4 Although
egimens with aminoglycosides have higher therapeutic suc-
ess rates, long-term use of such agents is associated with
igniﬁcant nephrotoxicity.
The use of quinolones for treating brucellosis is con-
roversial. Reported by several studies, monotherapy with
iproﬂoxacin results in an unacceptably high probability of
elapse.5–7 In four out of six randomized, controlled tri-
ls, oﬂoxacin was the quinolone used in combination with
ifampin. In three of these studies, the results were similar
etween the quinolone and the non-quinolone arms regarding
nitial treatment success and probability of relapse.8–10 In one
tudy of with spondylitis exclusively, the quinolone arm was
ound to be inferior to other treatment regimens in terms of
nitial treatment success and relapse rate.11 In two random-
zed, controlled trials, ciproﬂoxacin was the quinolone used,
ombined with doxycycline12 or rifampin13; the results were
imilar between the quinolone and the non-quinolone groups.
heoryhere are no studies in Egypt investigating the use
f triple antimicrobial therapy for brucellosis. The aim
f this study was to compare both the efﬁcacy and6;2 0(3):250–254 251
safety proﬁle of the WHO-recommended, dual antimicro-
bial therapy (doxycycline–rifampin) to a quinolone-based,
triple therapy (doxycycline–rifampin–levoﬂoxacin) for treating
acute/subacute brucellosis among Egyptian patients.
Patients  and  methods
The study included 120 consecutive, naïve patients with
acute/subacute brucellosis who had not received any antimi-
crobial therapy since the start of illness. The patients were
admitted to the departments of Tropical Medicine (Fever Unit)
and Internal Medicine during the period of May 2011 to
November 2014. Acute/subacute brucellosis was diagnosed
based on the presence of: (1) contact with animals or fresh
animal products, (2) suggestive clinical manifestations of
less than one-year duration (fever, chills, sweats, fatigue,
arthralgia, myalgia, relative bradycardia, splenomegaly, lym-
phadenopathy, and hepatomegaly), and (3) positive antibody
titer (1:160) by standard tube agglutination test (against Bru-
cella abortus, Brucella melitensis,  and Brucella suis). Pregnant and
pediatric patients were excluded from the study. We deﬁned
therapeutic failure as persistence of the clinical manifesta-
tions of brucellosis at end of treatment (after six weeks of
treatment). Relapse was deﬁned as recurrence of the clinical
manifestations with a single positive antibody titer within six
months after ending therapy.2
The study patients were randomly allocated to two  groups;
60 patients for each group. Group-A patients received the
WHO-recommended, dual antimicrobial therapy for brucel-
losis (doxycycline 200 mg/day and rifampin 900 mg/day, for
six weeks). Group-B patients received quinolone-based, triple
therapy (doxycycline 200 mg/day, rifampin 900 mg/day, and
levoﬂoxacin 500 mg/day, for six weeks). Each drug used was
produced by same pharmaceutical company and all drugs
were administered orally, once daily. Doxycycline was given
after breakfast; rifampin was given before breakfast; and
levoﬂoxacin was given 1 h before lunch. During inpatient
attendance, the patients were assessed clinically on a daily
basis; after discharge, they were assessed weekly on out-
patient clinic visits. Complete blood count, liver chemistry
panel, kidney chemistry panel, abdominal ultrasonography,
and chest radiography were performed before the start of
treatment. Laboratory investigations were repeated weekly to
monitor for side effects. Directly observed therapy was applied
during the period of inpatient attendance for all patients. The
patients were discharged after normalization of body tem-
perature for at least three days. After discharge, compliance
with therapy was conﬁrmed on weekly basis during outpa-
tient clinic visits. After the end of therapy, the patients were
assessed clinically on a monthly basis for six months to look
for evidence of relapse.
Ethical  considerations
The study was approved by the “Assiut Faculty of Medicine
Clinical Research Ethical committee”, and was carried out
in accordance with the Code of Ethics of the World Medi-
cal Association (Declaration of Helsinki). Before enrollment in
the study, all participants signed an informed consent. Before
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Table 1 – Demographic data of the study population
(n = 107) according to the group.
Group (A) (n = 53) Group (B) (n = 54) p-value
Age (years) 32.7 ± 15 36.2 ± 17.4 0.751
Gender (male) 32 (60.4%) 30 (55.6%) 0.416
Residence (rural) 41 (77.4%) 43 (79.6%) 0.947
Table 2 – Clinical manifestations of acute/subacute
brucellosis (n = 107).
Fever 103 (96.3%)
Fatigue 89 (83.2%)
Myalgia 75 (7.1%)
Chills 71 (66.4%)
Sweats 66 (61.7%)
Arthralgia 52 (48.6%)
Relative bradycardia 34 (31.8%)
Splenomegaly 23 (21.5%)
Hepatomegaly 18 (16.8%)
Lymphadenopathy 15 (14%)
n, number.
Table 3 – Adverse effects of antimicrobial therapy for
brucellosis (n = 107).
Epigastric pain 13 (12.1%)
Nausea and vomiting 10 (9.3%)
Diarrhea 9 (8.4%)
Fatigue 6 (5.6%)
Rash 3 (2.8%)
Heartburn 2 (1.9%)
Oral candidiasis 1 (1%)
n, number.
Table 4 – Outcome of antimicrobial therapy for
brucellosis according to the type of therapy (n = 107).
Outcome Group (A) (n = 53) Group (B) (n = 54) p-value
Therapeutic
failure
7  (13.2%) 6 (11.1%) 0.394
Relapse 12 (22.6%) 5 (9.3%) 0.010a
Adverse effects 6 (11.3%) 11 (20.4%) 0.059
15n, number.
signing, they were not able to discuss in details with the inves-
tigator the informed consent issues and the study aim. The
participants were clearly informed that refusing to participate
in the study would not affect having full beneﬁt of the available
medical service and treatment. Data were collected by per-
sonal interview with the participants taking in consideration
data conﬁdentiality.
Statistical  analysis
The data were entered into and then were analyzed using the
SPSS (version 22). Results were expressed as mean ± standard
deviation or frequency (percentage) as appropriate. The Chi-
square test or Fisher’s exact-test was used to analyze the
difference among categorical variables. Student’s t-test or
Mann–Whitney U test were used to analyze numeric variables
as appropriate. A p-value of less than 0.05 was considered
signiﬁcant.
Results
Out of the study population (120 patients), ﬁve were excluded
due to lack of compliance with antimicrobial therapy for bru-
cellosis (two patients of group-A and three of group-B). Eight
more patients were excluded due to inability to attend dur-
ing the required follow up period (six months after the end of
treatment) (ﬁve of group-A and three of group-B). After exclu-
sion of such cases, group-A consisted of 53 patients while
group-B had 54. Demographic data of the study population
(107 patients) according to the type therapy are shown in
Table 1. The mean age was 32.7 ± 15 and 36.2 ± 17.4 years,
respectively for group-A and group-B. There were 32 (60.4%)
males in group-A and 30 (55.6%) in group-B. There was no
signiﬁcant difference between the two groups regarding their
demographic data.
The clinical manifestations of acute/subacute brucellosis
in the study population are shown in Table 2. The most com-
mon  clinical manifestation was fever (96.3%).
Outcomes of antimicrobial therapy for brucellosis in the
study population included therapeutic failure in 13 patients
(12.1%), relapse in 17 (15.9%), and adverse effects of treatment
in 17 (15.9%).
The adverse effects of antimicrobial therapy for brucel-
losis in the study population are shown in Table 3. The most
commonly reported adverse effect was epigastric pain (12.1%).
Some patients had more  than one adverse effect either con-
comitantly or sequentially. No serious adverse effects were
reported among patients of either group.n, number.
a Statistically signiﬁcant.
The outcomes of antimicrobial therapy according to the
type of therapy used are shown in Table 4. Although the rate
of therapeutic failure was slightly higher in group-A (13.2%)
compared to group (B) (11.1%), this difference was not statisti-
cally signiﬁcant (p-value 0.394). However, the relapse rate was
signiﬁcantly higher in group-A (22.6%) compared to group-B
(9.3%) (p-value 0.010). Regarding the safety proﬁle of the used
regimens, the rate of adverse effects was higher in group-B
(20.4%) compared to group-A (11.3%), although this difference
did not reach statistical signiﬁcance (p-value 0.059).
Discussion
Human brucellosis has a major medical impact world-wide,
and its eradication deemed to be difﬁcult.14 With a sero-
prevalence of 1.29% among the general population in Assiut
Governorate (Egypt),1 brucellosis could be considered an
important public health issue in Egypt. The appropriate
antimicrobial therapy of brucellosis will reduce morbidity, pre-
vent complications, and diminish relapses. Up to 10% of
patients with brucellosis relapse after antimicrobial therapy.
The intracellular location of Brucella organisms predisposes
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o recurrence because the organisms are relatively protected
rom host defense mechanisms, and antimicrobial agents
ay be unable to penetrate efﬁciently enough to kill all
he bacteria.2 In vitro studies have demonstrated resistance
f Brucella to rifampin.16,17 In Egypt, Abdel-Maksoud et al.
eported resistance to rifampin and ceftriaxone among 355
rucella isolates analyzed that were susceptible to tetracycline,
oxycycline, trimethoprim-sulfamethoxazole, streptomycin,
nd ciproﬂoxacin.18
The main goal of this randomized, comparative study was
o compare the efﬁcacy and safety of the WHO-recommended,
ual antimicrobial therapy for acute/subacute brucellosis
doxycycline–rifampin) to a quinolone-based, triple antimi-
robial therapy (doxycycline–rifampin–levoﬂoxacin). In the
resent study, the use of triple antimicrobial therapy for bru-
ellosis has yielded both higher rate of persistent cure and
ower relapse rate within six months after stopping ther-
py compared to the dual antimicrobial therapy (9.3% versus
2.6%) among the study population, in spite of nearly equal
ates of clinical response and therapeutic failure after end-
ng six weeks of therapy (11.1% versus 13.2%). However, the
elapse rate among the study patients who received the
ual antimicrobial therapy was much more  higher than that
eported by Akova et al. (22.6% versus 3.3%),8 and also higher
han that reported by Karabay et al. (14.3% versus 22.6%),9 and
olera et al. in patients with acute brucellosis who received
he same treatment regimens (22.6% versus 16%)4 which raises
oncerns about the increasing development of microbial resis-
ance to the dual antimicrobial therapy for brucellosis in Egypt.
he lower efﬁcacy of the dual antimicrobial therapy could not
e attributed to any difference between the two groups of the
resent study.
In this study both regimens of antimicrobial therapy for
rucellosis (dual and triple) were considered safe and well-
olerated. No serious adverse effects of treatment were found.
he rates of adverse effects in both group-A (11.3%) and
roup-B (20.4%) patients were lower than that reported among
atients who received rifampin and doxycycline (43.3%)
lthough it was higher than that of patients who received
ifampin and oﬂoxacin (6.5%) reported by Akova et al.8 Only
ve (4.2%) out of 120 patients could not tolerate antimicro-
ial therapy for brucellosis and thus were excluded from the
tudy, with nearly no difference between the two groups (two
ut of 60 patients receiving the dual therapy and three out of
0 patients receiving the triple therapy).
As far as we know, no previous study had evaluated the
riple antimicrobial therapy (doxycycline plus rifampin plus
evoﬂoxacin) for treating brucellosis. One study has investi-
ated a different triple therapy for acute brucellosis. Ranjbar
t al. found that doxycycline–rifampin–amikacin has resulted
n a lower relapse rate (5.7%) compared to the dual antimi-
robial therapy (doxycycline–rifampin) (9.3%) with higher rate
f side effects in patients who received triple (5.5%) com-
ared to those who received dual antimicrobial therapy
3.6%), although the rates difference did not reach statistical
igniﬁcance.19 Previous studies of dual antimicrobial ther-
py for treating brucellosis revealed varying relapse rates
hen using rifampin combined with a quinolone. For use
f oﬂoxacin combined with rifampin, relapse rates ranged
etween 3.2%8 and 14.3%,9 and 15% when ciproﬂoxacin was6;2 0(3):250–254 253
combined with rifampin.13 Such results imply that using
a quinolone combined with rifampin for treating brucel-
losis usually yields higher relapse rates compared to using a
quinolone combined with rifampin and doxycycline such as
the triple antimicrobial therapy used for patients of group-B
in our study.
The present study has some limitations. The study sam-
ple is relatively small which was determined by availability
of cases diagnosed during the study period. We did not use
culture for conﬁrming the serologic diagnosis; microbiologi-
cal hazard of culturing Brucella organism made this choice a
remote one. Also, in spite of the instructions provided for the
study population to avoid contact with animals or fresh ani-
mal  products, compliance could not be guaranteed making
re-infection a potential cause for disease recurrence beside
relapse. However, exposure rates were similar among both
groups of the study. Also, in this study relapse was not con-
ﬁrmed by a rising antibody titer; rather, it was based on
recurrence of the clinical manifestations with a single pos-
itive antibody titer. Although we  assumed no antimicrobial
therapy before admission, this was based on both patients
and/or his/her relatives information in addition to revising
the patients’ prescriptions, this is not a 100% guarantee of not
having used antimicrobials before admission.
Conclusions
In conclusion, we found a higher than average relapse rate
of brucellosis in Egypt. Adding levoﬂoxacin to the WHO-
recommended, dual antimicrobial therapy for acute/subacute
brucellosis (doxycycline–rifampin) may increase its efﬁcacy in
the terms of lowering relapse rates within six months after
stopping therapy. However, it had no effect on the rate of
therapeutic failure after six weeks of therapy. The rate of
adverse effects for triple antimicrobial therapy for brucellosis
was slightly higher, but it did not affect patient compliance
or jeopardize safety. Further, larger scale studies are needed
before considering modifying the standard, dual antimicrobial
therapy for brucellosis in Egypt.
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